http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
Nanomedicines for breast cancer theranostics
Front Cover -- Nanomedicines for Breast Cancer Theranostics -- Nanomedicines for Breast Cancer Theranostics -- Copyright -- Contents -- Contributors -- Biography -- Preface -- Acknowledgment -- 1 -- Nanomedicine -- 1 -- Nanomedicine: next generation modality of breast cancer therapeutics -- 1.1 Introduction -- 1.1.1 Breast cancer -- 1.1.2 Breast cancer grading -- 1.1.3 Conventional breast cancer therapies -- 1.2 Cancer nanomedicine -- Acknowledgments -- References -- 2 -- Physical and chemical properties of nanomaterials -- 2.1 Introduction -- 2.2 Physical properties -- 2.2.1 Melting point
2.2.2 Mechanical properties -- 2.2.2.1 Hardness, plasticity, and Young's modulus/strength -- 2.2.3 Optical properties -- 2.2.4 Magnetic properties -- 2.2.4.1 Superparamagnetic behavior -- 2.2.4.2 Giant magnetoresistance (GMR) -- 2.2.4.3 Tunneling magnetoresistance (TMR) -- 2.3 Chemical properties -- 2.3.1 Surface energy -- 2.3.2 Chemical potential -- 2.3.3 Oxidation process at nanoscale -- 2.3.4 Catalysis -- 2.3.5 Functionalization of nanostructures -- 2.3.5.1 Surface functionalization -- 2.3.5.2 End wall functionalization -- 2.3.5.3 Inner wall functionalization -- References
3 -- Biological prospectives of hybrid nanostructures -- 3.1 Introduction -- 3.2 Hybrid nanostructures -- 3.3 Breast cancer -- 3.4 Current trends and challenges in treatments of breast cancer -- 3.5 Hybrid nanostructures in breast cancer nanotheranostics -- 3.5.1 Liposomal hybrid nanoparticles -- 3.5.2 Micelles hybrid nanostructures -- 3.5.3 Porous silica-based hybrid nanoparticles -- 3.5.4 Polymeric hybrid nanoparticles -- 3.5.5 Gold-based hybrid nanoparticles -- 3.5.6 Nanotube-based hybrid nanoparticles -- 3.6 Conclusion and future perspectives -- References
4 -- Novel hybrid nanostructure for breast cancer application -- 4.1 Introduction -- 4.2 Hybrid nanostructures in breast cancer applications -- 4.2.1 Liposomal hybrid nanostructures -- 4.2.2 Silica based hybrid nanostructures -- 4.2.3 Hybrid magnetic nanostructures -- 4.2.4 Gold based hybrid nanostructures -- 4.2.5 Carbon-based hybrid nanostructures -- 4.3 Conclusion -- References -- 2 -- Theranostics -- 5 -- Synergy between nanoparticles and breast cancer theranostics -- 5.1 Introduction -- 5.2 Nanoparticles for synergistic breast cancer diagnostics -- 5.2.1 Monomodal diagnostics
5.2.1.1 Fluorescence imaging (FI) -- 5.2.1.1.1 MCh-QDs -- 5.2.1.1.2 CQDs -- 5.2.1.1.3 SPDs -- 5.2.1.2 Computed tomography (CT) -- 5.2.1.3 Magnetic resonance imaging (MRI) -- 5.2.2 Bimodal diagnostics -- 5.2.2.1 FI and CT -- 5.2.2.2 FI and MRI -- 5.2.2.3 CT and MRI -- 5.2.3 Trimodal diagnostics -- 5.3 Nanoparticles for synergistic breast cancer therapeutics -- 5.3.1 Monomodal therapeutics -- 5.3.1.1 Chemotherapy (CHT) -- 5.3.1.2 Magnetic hyperthermia therapy (MHT) -- 5.3.1.3 Photodynamic/photothermal therapy (PDT/PTT) -- 5.3.2 Bimodal therapeutics -- 5.3.2.1 CHT and MHT -- 5.3.2.2 CHT and PDT/PTT
edited by Nanasaheb D. Thorat, Joanna Bauer.